1222. Risk Factors and Outcomes for Daptomycin Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

BACKGROUND: Daptomycin (dap) has been approved and successfully used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, reports of daptomycin nonsusceptible (DNS) MRSA strains have emerged over the recent years. This study describes the clinical characterist...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Hadid, Hind, Rizvi, Hira, Misikir, Helina, Baratz, Nathalie, Bardossy, Ana Cecilia, Sundaram, Ayesha, Haddad, Lillian, Perri, Mary Beth, Zervos, Marcus, Herc, Erica
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253196/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1055
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados